Literature DB >> 3049910

Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases.

G Camussi1, C Tetta, F Bussolino, C Baglioni.   

Abstract

TNF and IL-1 stimulate the synthesis and release of platelet-activating factor (PAF) by neutrophils and vascular endothelial cells. Serum inhibits PAF production even after inactivation of an acetylhydrolase that degrades PAF. Human plasma was fractionated by gel filtration chromatography, and two inhibitory fractions were detected, one containing PAF-acetylhydrolase activity and the other alpha 1-proteinase inhibitor. Low concentrations of this antiproteinase and of human plasma alpha 1-antichymotrypsin inhibited TNF-induced PAF synthesis in neutrophils, macrophages, and vascular endothelial cells. Both antiproteinases also inhibited PAF production stimulated by phagocytosis in macrophages and induced with IL-1 in neutrophils or with TNF in vascular endothelial cells. These results suggest that a proteinase activated on the plasma membrane or secreted by these cells is involved in promoting PAF synthesis. Indeed, addition of elastase to macrophages, neutrophils, and endothelial cells stimulated synthesis and release of PAF much faster than TNF. A similar stimulation was observed in incubations with cathepsin G. To identify a proteinase activated in TNF-treated cells, neutrophils and endothelial cells were incubated with specific chloromethyl ketone inhibitors of elastase and cathepsin G. Synthesis of PAF was significantly inhibited by low concentrations of the cathepsin G inhibitor. The finding that antiproteinases are inhibitory at concentrations 100-fold lower than those present in plasma raises questions as to the ability of TNF and IL-1 to stimulate neutrophils in circulation or endothelial cells to synthesize PAF. We propose that PAF production is limited to zones of close contact between cells, which exclude antiproteinases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049910      PMCID: PMC2189082          DOI: 10.1084/jem.168.4.1293

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  The role of platelet-activating factor in platelet aggregation.

Authors:  M Chignard; J P Le Couedic; M Tence; B B Vargaftig; J Benveniste
Journal:  Nature       Date:  1979-06-28       Impact factor: 49.962

2.  The release of a platelet-activating factor by stimulated rabbit neutrophils.

Authors:  J M Lynch; G Z Lotner; S J Betz; P M Henson
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils.

Authors:  G Camussi; M Aglietta; R Coda; F Bussolino; W Piacibello; C Tetta
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

4.  [Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine].

Authors:  J Benveniste; M Tencé; P Varenne; J Bidault; C Boullet; J Polonsky
Journal:  C R Seances Acad Sci D       Date:  1979-11-26

5.  Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha.

Authors:  F Bussolino; G Camussi; C Baglioni
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

6.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

7.  A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid).

Authors:  M L Blank; T Lee; V Fitzgerald; F Snyder
Journal:  J Biol Chem       Date:  1981-01-10       Impact factor: 5.157

8.  Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes.

Authors:  J M Mencia-Huerta; J Benveniste
Journal:  Eur J Immunol       Date:  1979-05       Impact factor: 5.532

9.  1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants.

Authors:  J T O'Flaherty; R L Wykle; C H Miller; J C Lewis; M Waite; D A Bass; C E McCall; L R DeChatelet
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

10.  Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor.

Authors:  J Benveniste; P M Henson; C G Cochrane
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  17 in total

1.  Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).

Authors:  N Imanishi; Y Komuro; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Protective effect of platelet activating factor antagonists on cultured endothelial cell lysis induced by elastase or activated neutrophils.

Authors:  P Renesto; P Vicart; D Paulin; M Chignard
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 3.  Mast cell modulation of the vascular and lymphatic endothelium.

Authors:  Christian A Kunder; Ashley L St John; Soman N Abraham
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

4.  Platelet-activating factor may participate in signal transduction processes in rabbit leukocytes.

Authors:  A G Stewart; T Harris
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

Authors:  Eli C Lewis; Leland Shapiro; Owen J Bowers; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

6.  Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor.

Authors:  I H Choi; T Y Ha; D G Lee; J S Park; J H Lee; Y M Park; H K Lee
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

7.  The primary elastase inhibitor (elastasin) and trypsin inhibitor (contrapsin) in the goat are serpins related to human alpha 1-anti-chymotrypsin.

Authors:  J Potempa; J J Enghild; J Travis
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

8.  Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment.

Authors:  R M Barr; F Lawlor; M R Judge; P Courtney; R Barlow; A Kobza Black; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

9.  Transient activation of 1-O-alkyl-sn-glycero-3-phosphocholine: acetyl-CoA acetyltransferase during the incubation of macrophages.

Authors:  T Sugiura; T Fukuda; N N Cheng; K Waku
Journal:  Lipids       Date:  1991-11       Impact factor: 1.880

10.  The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.

Authors:  Enrico Lupia; Lorenzo Del Sorbo; Serena Bergerone; Giorgio Emanuelli; Giovanni Camussi; Giuseppe Montrucchio
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.